ECR 2010 / C-0251
Clinical impact of 18F-FDG-PET/CT in the staging and management of patients with hepatobiliary malignancy
Authors:
C. N. Patel, R. Briggs, F. U. Chowdhury, A. F. Scarsbrook; Leeds/UK
DOI:
10.1594/ecr2010/C-0251
References
KEY REFERENCES
- Delbeke D and Martin WH. Update of PET and PET/CT for hepatobiliary and pancreatic malignancies. HPB 2005; 7:166-179
- Gambhir SS et al. A tabulated summary of the FDG PET literature. J Nucl Med 2001; 42(suppl):9S-12S
- Strauss LG, Dimitrakopoulou-Strauss A. Can PET-CT replaced contrast enhanced CT for imaging liver metastases. Eur J Nucl Med Mol Imag 2007; 34:1202-5
- Strasberg SM et al. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study. Ann Surg 2001; 233:293-9
- Cohade C et al. Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med 2003; 44:1797-1803
- Breitenstein S et al. Positron emission tomography (PET) for cholangiocarcinoma. HPB 2008; 10:120-121
- Keiding S et al. Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography. Hepatology 1998; 28:700-706
- Kim YJ et al. Usefulness of 18F-FDG PET in intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imag 2003; 30:1467-1472
- Fritscher-Ravens A et al. FDG PET in the diagnosis of hilar cholangiocarcinoma. Nucl Med Comms 2001; 22:1277-1285
- Anderson CD et al. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg 2004; 8:90-97
- Petrowsky H et al. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol 2006; 45:43-50